- Home
- PRLD vs ACRV Comparison
PRLD vs ACRV Comparison
Compare PRLD & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- ACRV
- Stock Information
- Founded
- PRLD 2016
- ACRV 2018
- Country
- PRLD United States
- ACRV United States
- Employees
- PRLD N/A
- ACRV N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- PRLD Health Care
- ACRV Health Care
- Exchange
- PRLD Nasdaq
- ACRV Nasdaq
- Market Cap
- PRLD 44.0M
- ACRV 41.7M
- IPO Year
- PRLD 2020
- ACRV 2022
- Fundamental
- Price
- PRLD $1.19
- ACRV $1.65
- Analyst Decision
- PRLD Strong Buy
- ACRV Buy
- Analyst Count
- PRLD 3
- ACRV 7
- Target Price
- PRLD $4.00
- ACRV $17.40
- AVG Volume (30 Days)
- PRLD 223.1K
- ACRV 3.3M
- Earning Date
- PRLD 11-05-2025
- ACRV 08-13-2025
- Dividend Yield
- PRLD N/A
- ACRV N/A
- EPS Growth
- PRLD N/A
- ACRV N/A
- EPS
- PRLD N/A
- ACRV N/A
- Revenue
- PRLD $7,000,000.00
- ACRV N/A
- Revenue This Year
- PRLD N/A
- ACRV N/A
- Revenue Next Year
- PRLD N/A
- ACRV $805.34
- P/E Ratio
- PRLD N/A
- ACRV N/A
- Revenue Growth
- PRLD N/A
- ACRV N/A
- 52 Week Low
- PRLD $0.61
- ACRV $1.05
- 52 Week High
- PRLD $5.53
- ACRV $10.00
- Technical
- Relative Strength Index (RSI)
- PRLD 56.86
- ACRV 65.93
- Support Level
- PRLD $1.10
- ACRV $1.30
- Resistance Level
- PRLD $1.26
- ACRV $2.67
- Average True Range (ATR)
- PRLD 0.15
- ACRV 0.17
- MACD
- PRLD -0.00
- ACRV 0.04
- Stochastic Oscillator
- PRLD 70.65
- ACRV 27.14
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.